Cytomatrix forms nanofibre joint venture
Melbourne-based stem cell company Cytomatrix has formed a joint venture with Switzerland’s HeiQ Materials to support the commercialisation of a stem cell solution for bone marrow transplants.
The new joint venture, HeiQ Australia, will produce the nanofibre materials required for the manufacturing of Cytomatrix’s 3D off-the-shelf haemopoietic stem cell (HSC) technology.
A new manufacturing facility has been established in Geelong in partnership with Deakin University and the Advanced Manufacturing Cooperative Research Centre (AMCRC).
The nanofibre technology forms one of four components in Cytomatrix’s 3D stem cell expansion system. The company expects that the technology will allow stem cells to be produced at sufficient volumes to treat all patients requiring bone marrow transplants for the first time.
As part of the partnership, HeiQ will invest up to $4 million in manufacturing scale-up and research into improved production methods. Cytomatrix will retain an exclusive supply of short nanofibres into pharmaceutical applications.
HeiQ Materials CTO Dr Murray Height will lead the new joint venture.
“This is a superb outcome from the research collaboration between Cytomatrix, the Advanced Manufacturing CRC and Deakin University,” Cytomatrix CSO Associate Professor Mark Kirkland said.
“The short nanofibre technology platform has applications across several pharmaceutical and industrial applications.”
Scientists find new driver of ovarian cancer spread
A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
